HRT is not working for me. Now what?

Updated August 3, 2026 · 14 min read

Hormone therapy is the most effective treatment for hot flashes and night sweats, and for a lot of women it is genuinely transformative. For others it does very little, causes side effects that outweigh the benefit, or is not an option at all. That is not a personal failure and it is not the end of the road. Some of it is fixable with a dose, a route, or a progestogen change. Some of it means the symptom was never estrogen-driven. And the non-hormonal options are better in 2026 than they have ever been, including two newly approved drugs that target the hot flash circuit in the brain directly.

You did the hard part. You got the appointment, you asked for the thing, you took it for three months, and you are still awake at 3 a.m. wondering what is wrong with you. Nothing is wrong with you. There are about eight more levers, and most women are never told any of them exist.

The short version

Give it a fair trial, then act. Twelve weeks at an adequate dose is the usual decision point. Six months of hoping is not a plan.
"HRT failed" often means "this dose and route failed." Dose, delivery method, and which progestogen you use are three separate variables, and most women only ever try one combination.
Rule out the imitators. Thyroid disease, iron deficiency, sleep apnea, depression, and B12 deficiency produce the same symptom list and do not respond to estrogen.
There are three FDA-approved non-hormonal drugs for flashes. Low-dose paroxetine 7.5 mg, fezolinetant (Veozah, 2023), and elinzanetant (Lynkuet, 2025).
Non-drug options have real evidence. CBT and clinical hypnosis are both endorsed by The Menopause Society for vasomotor symptom bother, and CBT-I is first-line for insomnia.
Compounded pellets are not the answer. No major society recommends them, and the dose cannot be taken back out.

First, is it actually not working?

Different symptoms respond on different clocks. Hot flashes and night sweats typically begin easing within two to four weeks and reach their full effect around eight to twelve weeks. Sleep tends to improve as the night sweats settle rather than immediately. Mood often takes six to eight weeks. Local vaginal estrogen for dryness, painful sex, or recurrent urinary symptoms can take a full three months, and it is frequently abandoned at week four by women who were never told that. Joint pain and brain fog are the least predictable of all, and the honest answer is that some women get striking relief and others get none.

This is also where tracking earns its keep. "It is not working" is hard to act on. "My flashes went from nine a day to six, my sleep is unchanged, and my mood is worse in the ten days I take the progesterone" tells a clinician exactly which lever to pull.

The fixable reasons HRT underperforms

1. The dose is too low

Starting low is correct practice, but starting low and never reviewing is not. Perimenopausal women often need more estradiol than postmenopausal women because they are treating erratic peaks and troughs rather than a flat deficiency. If your symptoms improved a little and then stalled, a dose review at six to eight weeks is the standard next step, not a reason to give up.

2. The route is wrong for your body

Transdermal estradiol (patch, gel, or spray) is generally preferred because it avoids the first-pass liver effect and does not carry the clot risk that oral estrogen does. But absorption varies a lot between people and between application sites, and some women simply do not absorb gel well. Patches can fail in heat and humidity, ironically at exactly the time of year flashes are worst. Switching patch to gel, gel to spray, or splitting a dose across the day are all reasonable experiments. This is one of the few situations where checking a serum estradiol level is genuinely informative.

3. The progestogen is the problem

If the bad days line up with the progestogen phase, the estrogen may be working fine and being drowned out. Progestogen intolerance looks like low mood, irritability, bloating, breast tenderness, or heavy fatigue. Documented workarounds include micronized progesterone instead of a synthetic progestin, taking it at night for its sedative effect, a levonorgestrel intrauterine system so the effect stays mostly local, long-cycle regimens, or the estrogen plus bazedoxifene combination that protects the uterus without any progestogen. What you must not do is drop the progestogen and keep taking systemic estrogen if you have a uterus.

4. You are still cycling

Perimenopause is not a smooth decline. Estradiol can spike higher than it ever did in your thirties and then crash. Layering a fixed dose over that can produce a period of feeling more volatile, not less, and it is why perimenopausal HRT often needs more adjustment than postmenopausal HRT. A combined oral contraceptive is sometimes used instead in this window, because suppressing your own cycle and replacing it with a steady dose can be more stable than adding to it.

5. It was never an estrogen problem

This is the one that gets missed most. Thyroid dysfunction, iron deficiency, obstructive sleep apnea, depression, anxiety disorders, undiagnosed ADHD, B12 deficiency, and early diabetes all overlap heavily with the perimenopause symptom list. Fatigue, fog, low mood, palpitations and poor sleep are not specific. A reasonable workup includes thyroid function, full blood count and ferritin, vitamin D, B12, HbA1c, and a sleep apnea screen if you snore or wake unrefreshed. If HRT did nothing whatsoever, this is the section to take to your appointment.

The new non-hormonal drugs, explained

A hot flash is not a hormone leaking heat. It is a thermoregulatory misfire. In the hypothalamus, a group of neurons known as KNDy neurons normally sits under an estrogen brake. When estrogen falls, they enlarge and over-fire, and the signalling molecules they use, neurokinin B in particular, push the temperature control centre into dumping heat. Two drugs now block that signal directly.

Fezolinetant (Veozah)

An NK3 receptor antagonist, FDA-approved in 2023 for moderate to severe vasomotor symptoms due to menopause. One 45 mg capsule daily, no hormones involved. In trials it reduced hot flash frequency and severity substantially versus placebo, with effect visible in the first weeks. It requires liver function testing before starting and periodically after, and the FDA added a warning about rare serious liver injury in 2024. It is contraindicated in cirrhosis, severe kidney impairment, and with CYP1A2 inhibitors.

Elinzanetant (Lynkuet)

Approved in the US in 2025, this one blocks both NK1 and NK3 receptors, and it is the third FDA-approved non-hormonal option for moderate to severe hot flashes. The dual mechanism appears to add benefit for sleep disturbance and overall menopause-related quality of life alongside the flash reduction. Common side effects are headache, fatigue, dizziness and sleepiness. It also requires baseline and follow-up liver enzyme testing at around three months, must not be used in pregnancy, and carries a caution in anyone with a seizure history.

Both matter most for two groups: women who cannot take estrogen at all, particularly breast cancer survivors, and women whose flashes persisted or who could not tolerate hormone therapy. Neither replaces what estrogen does for bone, urogenital tissue, or the wider symptom set. They are precision tools for vasomotor symptoms.

One perimenopause-specific caveat: both drugs are labelled for hot flashes due to menopause and their pivotal trials mainly enrolled postmenopausal women. If you are still cycling, they are not off the table, but a clinician is making a judgement call rather than following the label, and they do nothing for the erratic bleeding, cycle-linked mood shifts, or heavy periods that often drive perimenopausal prescribing in the first place.

The rest of the evidence-based non-hormonal list

Low-dose paroxetine 7.5 mg. The only SSRI formally FDA-approved for vasomotor symptoms. Avoid it if you take tamoxifen, because it interferes with tamoxifen metabolism.
Other SSRIs and SNRIs. Escitalopram, citalopram, venlafaxine and desvenlafaxine all have supporting trial data for flashes, and are useful when mood symptoms are also present.
Gabapentin. Particularly effective for night sweats because it is dosed at bedtime and the sedation is a feature rather than a bug.
Oxybutynin. Reduces flashes, and is worth knowing about, though anticholinergic burden means it is not usually a long-term first choice.
CBT for menopause. Endorsed by The Menopause Society for reducing symptom bother and improving sleep and mood, and now available in structured digital formats. It does not reduce flash frequency much; it substantially reduces how much they cost you.
CBT-I. First-line for chronic insomnia, hormones or not, and more durable than any sleep medication.
Clinical hypnosis. One of the few complementary approaches with genuine trial support for hot flash reduction.
Weight management and stopping smoking. Both are associated with fewer and less severe vasomotor symptoms, and both are slow levers rather than quick fixes.
Vaginal and urinary symptoms, treated separately.Low-dose vaginal estrogen, prasterone (vaginal DHEA), ospemifene, or non-hormonal moisturisers and lubricants. Systemic HRT often does not fully resolve these even when it works well elsewhere, which surprises a lot of women.
Testosterone, in the right case. Not a treatment for flashes, fatigue, or fog, but there is evidence for low sexual desire that persists after estrogen is optimised. It is off-label for women in the US and needs monitoring.

What to skip, and why

Compounded hormones and pellets. Not recommended by The Menopause Society, ACOG, or the Endocrine Society. Inconsistent dosing, no regulatory oversight, and pellets cannot be removed.
Salivary and "hormone panel" home testing. No clinical validity in a fluctuating perimenopausal cycle.
Most botanical flash cures. Black cohosh, red clover, evening primrose oil and soy isoflavone supplements perform close to placebo in pooled trials. Not dangerous, just not the answer.
Waiting it out silently. Vasomotor symptoms last a median of seven to ten years in the SWAN cohort. That is a long time to spend as an experiment with no follow-up appointment.

A practical sequence for the next 12 weeks

Weeks 1 to 4: log symptoms daily. Frequency and severity of flashes, wake-ups, mood, and where you are in the cycle or the progestogen phase.
Week 4: book the review and get the imitator bloods done at the same time so the results are ready.
Week 5 or 6: change one variable. Dose, route, or progestogen. One at a time, or you will not know what helped.
Weeks 6 to 12: keep logging. Compare against your own baseline rather than against how you think you should feel.
Week 12: if two adjustments have not moved the needle, ask for a referral to a menopause specialist and ask specifically about non-hormonal options by name.

Get medical help sooner if

You have calf pain or swelling, chest pain, or shortness of breath, which need same-day assessment.
You develop new migraine with aura or sudden severe headache.
You have unexplained vaginal bleeding, bleeding after sex, or bleeding that starts after 12 months without a period.
You notice yellowing of the eyes or skin, dark urine, or right upper abdominal pain while taking fezolinetant or elinzanetant.
Your mood is persistently low, or you have any thoughts of self harm. In the US, call or text 988.

How PeriSlayer helps when treatment is not working

The hardest part of adjusting treatment is remembering what actually changed. PeriSlayer logs your symptoms in about 15 seconds a day and looks for the connections across sleep, mood, cycle timing, and flashes, so you can see whether the new dose moved anything and whether the bad days cluster around the progestogen phase. Then it turns that into a clear summary you can hand to a clinician, which is the difference between "it is not really working" and a specific request for a specific change.

What else is inside PeriSlayer

PeriSlayer is more than a tracker and a doctor summary. It is a whole place to land while you figure this stretch of life out.

Peri-Pals community. An in-app forum where you can ask the question you have been too tired to Google, under a fun anonymous name. Someone in there is going through the same thing this week, and they will tell you what actually helped.
The AI pattern engine. Fifteen-second check-ins on sleep, mood, cycle, and symptoms. After about a week it starts connecting them into patterns you would never spot from memory.
Pilates built for perimenopause. Gentle sessions designed by our Pilates pro, suggested to match what your logs are showing: joint-pain week, sleep-wrecked week, low-energy week.
A summary for your appointment. Your logs turned into a clear, one-page picture you can hand to a clinician, so the visit starts with evidence instead of guessing.
Playlists and weekly horoscopes. Mood-matched playlists and a warm, slightly sarcastic weekly wink for every sign, for the days when the data is a lot.

The iOS beta is opening soon. Join the beta list and you will be in the community from day one.

Sources & further reading

We cite peer-reviewed research and clinical guidance from NIH, the Menopause Society, ACOG, NICE, and other independent bodies. Follow the links for the primary source.

1.Nonhormonal management of vasomotor symptoms: 2023 position statement — The Menopause Society (NAMS)
2.2022 Hormone Therapy Position Statement — The Menopause Society (NAMS)
3.NG23: Menopause — identification and management — NICE (UK)
4.LYNKUET (elinzanetant) prescribing information, initial U.S. approval 2025 — DailyMed, U.S. National Library of Medicine
5.FDA approves nonhormonal treatment for menopausal hot flashes — JAMA (2025)
6.VEOZAH (fezolinetant) drug safety communication on rare liver injury — U.S. Food and Drug Administration
7.Nonhormonal treatments for hot flashes — Mayo Clinic Press (July 2026)
8.Study of Women's Health Across the Nation (SWAN) — NIH-funded longitudinal cohort
9.Menopause and perimenopause overview — NIH · National Institute on Aging
10.Menopause practice guide — The Menopause Society (NAMS)
11.The Menopause Years (patient FAQ) — ACOG

Frequently asked questions

How long should HRT take to work?

Hot flashes and night sweats usually start improving within 2 to 4 weeks and settle by about 8 to 12 weeks. Sleep often follows the vasomotor symptoms. Mood can take 6 to 8 weeks. Vaginal dryness and urinary symptoms treated with local vaginal estrogen can take 8 to 12 weeks for the full effect. Joint aches and brain fog are the least predictable. If nothing at all has shifted after three months at an adequate dose, that is the point to change something rather than wait longer.

Why would HRT not work for me?

The most common reasons, in rough order of frequency: the dose is too low for your symptom burden, the route is wrong for your absorption (some women absorb patches or gels poorly), the progestogen is causing side effects that mask the estrogen benefit, you are still cycling so your own estradiol is swinging on top of the therapy, the trial was too short, or the symptom was never estrogen-driven in the first place. That last category matters: thyroid disease, iron deficiency, sleep apnea, depression, ADHD, and B12 deficiency all imitate perimenopause and none of them respond to estrogen.

What are the non-hormonal prescription options for hot flashes?

There are now three FDA-approved non-hormonal options for moderate to severe vasomotor symptoms: low-dose paroxetine (7.5 mg, the only approved SSRI for this use), fezolinetant (Veozah, an NK3 receptor antagonist approved in 2023), and elinzanetant (Lynkuet, an NK1 and NK3 receptor antagonist approved in 2025). Their labelled indication is hot flashes due to menopause, and the trials mostly enrolled postmenopausal women, so prescribing them during perimenopause is a clinical judgement your clinician makes rather than an on-label use. Beyond those, The Menopause Society's non-hormonal position statement supports SSRIs and SNRIs such as escitalopram and venlafaxine, gabapentin (particularly for night sweats), oxybutynin, cognitive behavioural therapy, and clinical hypnosis, all of which are routinely used in perimenopause. Fezolinetant and elinzanetant both require liver enzyme monitoring before and during treatment.

What are fezolinetant and elinzanetant, and are they as good as HRT?

Both are neurokinin receptor antagonists. They work on the KNDy neurons in the hypothalamus that lose their estrogen brake during the transition and start over-firing the temperature control centre, which is what a hot flash actually is. They target that circuit directly instead of replacing hormones. In trials both roughly halve hot flash frequency and severity, which is somewhat less than systemic estrogen achieves but clinically meaningful, and elinzanetant also showed benefit for sleep disturbance. They do nothing for bone density, vaginal symptoms, or anything else estrogen covers, so they are a vasomotor treatment rather than an HRT substitute. Both need transaminase testing at baseline and during the first months, and elinzanetant carries warnings about pregnancy loss and seizure history.

Can the progesterone part be the problem rather than the estrogen?

Frequently, yes. Progestogen intolerance shows up as low mood, irritability, bloating, breast tenderness, or fatigue that starts with the progestogen phase. Options your clinician can consider include switching to micronized progesterone (often better tolerated than synthetic progestins), moving it to bedtime to use the sedative effect, changing to a levonorgestrel intrauterine system so the dose acts mainly on the uterus, using a longer-cycle regimen, or in some cases the estrogen plus bazedoxifene combination, which provides uterine protection without a progestogen at all. Do not simply stop the progestogen while continuing systemic estrogen if you still have a uterus. That raises endometrial cancer risk.

What if HRT made my symptoms worse?

Worsening in the first few weeks is common and often settles, but it should be reported rather than endured. Breast tenderness, nausea, and headaches often mean the dose is too high or the route needs changing (oral estrogen has a first-pass liver effect that transdermal avoids). Cyclical low mood usually points at the progestogen. New migraines with aura, calf pain or swelling, chest pain, or shortness of breath are urgent and need same-day assessment. In perimenopause specifically, adding a steady dose of estrogen on top of your own erratic peaks can feel worse before it feels better, which is one argument for starting low and reviewing at six weeks.

What if I cannot take HRT at all?

The main contraindications are current or recent breast cancer, an estrogen-dependent cancer, active or recent blood clots, unexplained vaginal bleeding, active liver disease, and untreated endometrial hyperplasia. If that is you, the non-hormonal route is the plan, not a consolation prize: an NK receptor antagonist or an SSRI or SNRI for flashes, gabapentin for night sweats, CBT for symptom bother and sleep, and CBT-I for insomnia. Vaginal symptoms are treated separately, and low-dose vaginal estrogen is often still considered acceptable after breast cancer in discussion with your oncologist, because systemic absorption is minimal. Non-hormonal options for vaginal symptoms include prasterone (vaginal DHEA), ospemifene, hyaluronic acid moisturisers, and vaginal laser as a less well-evidenced option.

Should I try compounded bioidentical hormones instead?

No. Compounded hormone preparations, including pellets and troches, are not recommended by The Menopause Society, ACOG, or the Endocrine Society. They are not FDA-approved, the dosing is inconsistent between batches, pellets cannot be removed if the level is too high, and the claim that they are safer than regulated body-identical hormones is not supported by evidence. If you want body-identical hormones, transdermal estradiol plus oral micronized progesterone is already exactly that, in a regulated dose.

Do I need to test my hormone levels to find out why HRT is not working?

Usually not. Perimenopausal hormone levels swing too much for a single sample to mean much, and treatment is titrated to symptoms rather than to a number. There are exceptions where clinicians do check estradiol: suspected poor absorption of a patch or gel, unusually high doses, or non-oral routes where the response does not match the dose. Salivary hormone testing has no clinical validity and should be skipped. What is worth testing is the imitators: thyroid function, ferritin and full blood count, vitamin D, B12, and HbA1c, plus a sleep apnea screen if you snore or wake unrefreshed.

Is it worth seeing a menopause specialist?

If two dose or route adjustments have not helped, yes. A Menopause Society certified practitioner (searchable on menopause.org) or a British Menopause Society specialist in the UK will usually try things a general practice will not: split dosing, higher transdermal doses, alternative progestogens, adding testosterone where low desire is the main issue, or combining hormonal and non-hormonal treatment. Bring a symptom log of at least four to six weeks. The single most useful thing you can hand a specialist is a record showing what changed, when, and by how much.

Track your own patterns

PeriSlayer is a warm, private iOS app for logging perimenopause symptoms and spotting the patterns nobody else will connect for you.

Join the waitlist